Researchers apply PNC-27 to investigate its selective binding to HDM-2 expressed on cancer cell membranes, resulting in transmembrane pore formation and rapid necrotic cell death. Pre-clinical observations in multiple cancer cell lines (pancreatic, breast, ovarian, leukemia) indicate co-localization with membrane HDM-2 in transformed cells, with no equivalent interaction in untransformed cells.
This chimeric peptide facilitates examination of cancer cell-specific membrane disruption, rapid release of intracellular contents, and selective cytotoxicity profiles in in vitro and in vivo tumor models.
Scientific Overview of PNC-27 Applications
Pre-clinical models demonstrate PNC-27’s engagement with membrane-associated mechanisms:
- Selective binding to HDM-2 on cancer cell membranes, inducing transmembrane pore formation and rapid necrosis in pancreatic, breast, ovarian, and leukemia cell lines. https://pubmed.ncbi.nlm.nih.gov/20080680/
- Co-localization with HDM-2 in cancer cell membranes but not in normal or untransformed cells, supporting cancer-specific targeting. https://pubmed.ncbi.nlm.nih.gov/25117093/
- Induction of tumor cell lysis with LDH release within hours in multiple transformed cell types without affecting normal cell viability.
- Tumor eradication in nude mouse xenograft models (pancreatic, melanoma) following administration with no observed off-target toxicity. https://pubmed.ncbi.nlm.nih.gov/22493585/
- Support for investigations into synergy with chemotherapeutic agents in ovarian cancer cell models.
- Examination of HDM-2 membrane expression as a distinguishing feature between cancer and normal cells in preclinical systems.
For further details on HDM-2 membrane targeting, selective necrotic peptides, and cancer cell signaling in pre-clinical research, refer to the Peptide Sciences or About Peptides sections.
Why Investigators Select National Science Labs PNC-27
National Science Labs manufactures PNC-27 under stringent GMP-compliant protocols to ensure batch-to-batch consistency and reliability for pre-clinical experiments. Independent third-party testing verifies each lot for:
- Purity ≥99.9% by HPLC
- Structural identity confirmation via mass spectrometry
- Complete Certificate of Analysis (CoA) documentation provided per batch
For Research Use Only. This product is supplied exclusively for in vitro and in vivo pre-clinical research by qualified investigators. Statements about this peptide have not been evaluated by the FDA.
Initiate Your PNC-27 Research Protocol
Source high-purity PNC-27 from current limited batches to ensure optimal stability and performance in HDM-2 targeting and cancer cell studies.
